Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
about
Molecularly targeted therapy for advanced hepatocellular carcinoma - a drug development crisis?Protein tyrosine phosphatases as wardens of STAT signalingA systems model of phosphorylation for inflammatory signaling eventsDovitinib: rationale, preclinical and early clinical data in urothelial carcinoma of the bladder.Alteration of SHP-1/p-STAT3 Signaling: A Potential Target for Anticancer Therapy.Phase Ib study of dovitinib in combination with gemcitabine plus cisplatin or gemcitabine plus carboplatin in patients with advanced solid tumorsSC-2001 overcomes STAT3-mediated sorafenib resistance through RFX-1/SHP-1 activation in hepatocellular carcinomaThe anticancer multi-kinase inhibitor dovitinib also targets topoisomerase I and topoisomerase II.Oncolytic immunotherapy using recombinant vaccinia virus GLV-1h68 kills sorafenib-resistant hepatocellular carcinoma efficiently.The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistanceProtein tyrosine phosphatase SHP-1 sensitizes EGFR/HER-2 positive breast cancer cells to trastuzumab through modulating phosphorylation of EGFR and HER-2.Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinomaMcl-1-dependent activation of Beclin 1 mediates autophagic cell death induced by sorafenib and SC-59 in hepatocellular carcinoma cells.SH2 domain-containing phosphatase 1 regulates pyruvate kinase M2 in hepatocellular carcinoma.Purity of transferred CD8(+) T cells is crucial for safety and efficacy of combinatorial tumor immunotherapy in the absence of SHP-1.Mechanisms of STAT3 activation in the liver of FXR knockout mice.Novel sorafenib analogues induce apoptosis through SHP-1 dependent STAT3 inactivation in human breast cancer cells.Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status.Targeting STAT3 in gastric cancer.Antiangiogenic treatment in hepatocellular carcinoma: the balance of efficacy and safety.Role of the fibroblast growth factor receptor axis in cholangiocarcinoma.Targeting the tumor stroma in hepatocellular carcinoma.Natural product pectolinarigenin inhibits osteosarcoma growth and metastasis via SHP-1-mediated STAT3 signaling inhibition.Sorafenib with ASC-J9® synergistically suppresses the HCC progression via altering the pSTAT3-CCL2/Bcl2 signals.Implication of protein tyrosine phosphatase SHP-1 in cancer-related signaling pathways.Protein tyrosine phosphatase 1B dephosphorylates PITX1 and regulates p120RasGAP in hepatocellular carcinoma.Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma.Momordica charantia lectin exhibits antitumor activity towards hepatocellular carcinoma.Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity.Preclinical evaluation of combined TKI-258 and RAD001 in hepatocellular carcinoma.Cellular and molecular targets for the immunotherapy of hepatocellular carcinoma.Dovitinib enhances temozolomide efficacy in glioblastoma cells.MicroRNA-486-5p enhances hepatocellular carcinoma tumor suppression through repression of IGF-1R and its downstream mTOR, STAT3 and c-Myc.MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.The tyrosine kinase inhibitor nintedanib activates SHP-1 and induces apoptosis in triple-negative breast cancer cells.Amentoflavone enhances sorafenib-induced apoptosis through extrinsic and intrinsic pathways in sorafenib-resistant hepatocellular carcinoma SK-Hep1 cells in vitro.Dovitinib induces mitotic defects and activates the G2 DNA damage checkpoint.
P2860
Q26766689-BFDC4E6F-7F97-467B-B763-84A275595D33Q26861574-CCC7DA93-1A4F-41C6-834A-88AFE038EC8EQ28543980-9A3DE407-64D5-42FF-85A0-508AFD84CE7CQ30857433-96AFA04F-3FE5-4425-8AD5-01033DBB464AQ33838824-B6CE2DF8-6C63-4D61-8B52-8E53E0FDBB30Q34097937-A8B4712E-230A-419C-82A4-56F7968D0D78Q34347235-3DDABCE9-3734-41C2-9AFB-428990B1031DQ34435367-0FC061E2-2CDE-4708-9F5D-6230F17BF17BQ34438331-F39A414A-080F-43B2-B85F-7CC68FAA183DQ35045419-E42819B6-C83F-43C0-B217-A2F5CD9C327DQ36078326-B0E477CF-C898-459F-8F3C-F75D374E4B41Q36555872-7B9A0B6C-AF4F-4FC6-A95D-B42E7F26D060Q37049104-FAFBC651-E458-4D88-A9B0-B463B7ED16C5Q37073574-689DA8CD-D44A-4823-95C8-7836579FCC86Q37225507-7CB2CCA5-5775-4C2A-B9C7-EB5961082DB1Q37263972-743C24CB-7344-403C-A8AC-3CB7EDEB86FCQ37440079-BD65CF79-B517-4107-901E-C98FAC75BE12Q37690338-6678BFA9-DB26-40D5-9E1F-F7E6FEA89826Q37717519-8DD5C0E7-A69D-49B6-AE17-C3EE4FD1FFADQ38029729-E9BD7B52-68C0-4EDB-8123-8F6E45C08414Q38160838-7953A3EA-5342-4025-8FD7-8ABF8E5FB8FCQ38354294-17C4DE39-4F39-46BB-8F82-F9C905186079Q38366586-AC7718DF-2DD7-42EE-85C1-C50A06E41C07Q38741382-4A982276-961F-452E-A9C9-EE66F29C869DQ38743727-91697205-C262-4AC2-9B38-58170D9E977EQ38778743-DC3D0E33-4399-4530-9A82-2286EC290F3EQ38796951-3994B4EC-5527-4ABA-836C-A1FD9A84E507Q38801405-66345FED-2BEC-41F1-9B35-02C529A585DFQ38923977-536D8B17-AB2F-4F08-90FA-52F57F997421Q38958526-F1862035-56B1-48A0-8F38-9D8408E05243Q39062384-0851A835-ACAD-499A-B991-1FB758AD858FQ39172796-F9B8BD65-6E1B-47BF-8CEC-2894B46F3A6EQ39358916-2D018ECF-8519-479B-B56C-4FF648F244EAQ40214485-8436A357-C498-4675-BADA-12385B0CD3BEQ40555570-0009E3C3-F45F-468B-9833-E71C8CE5FFC8Q41126784-98494AA8-2135-49DF-86A1-E91486D872B3Q41127816-027BF78F-0A0F-4B04-A616-AC00CEC78749Q41583233-1ACAD023-FB2C-4A1B-8524-32F4C44F3AEDQ41615015-F7165C7B-E291-47C3-BA45-43DC293655B2Q41923223-469E02B4-9661-40AD-A708-C6C9976B2D55
P2860
Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@en
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@nl
type
label
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@en
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@nl
prefLabel
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@en
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@nl
P2093
P50
P1476
Dovitinib induces apoptosis an ...... -mediated inhibition of STAT3.
@en
P2093
Ching-Huai Ko
Chun-Yu Liu
Chung-Wai Shiau
Mai-Wei Lin
Wei-Tien Tai
P304
P356
10.1158/1535-7163.MCT-11-0412
P577
2011-12-16T00:00:00Z